Neoantigens and Microenvironment in Type 1 Diabetes: Lessons from Antitumor Immunity

Trends in Endocrinology and Metabolism

Volumn 27, Issue 6, 2016, Pages 353-362

  Kracht, Maria J L ^a   Zaldumbide, Arnaud ^a   Roep, Bart O ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Autoreactive T cells; Cancer; Diabetes; Immunotherapy; Neoantigens; Pancreatic beta cells

Indexed keywords

ANTIGEN; EPITOPE;

ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; DIABETOGENESIS; DISEASE COURSE; HUMAN; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; RNA EDITING; SOMATIC MUTATION; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASM; PHYSIOLOGY;

ANIMALS; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOTHERAPY; INSULIN-SECRETING CELLS; NEOPLASMS; T-LYMPHOCYTES;

EID: 84963574945     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2016.03.013     Document Type: Review

References (99)

1. Abreu J.R., et al. CD8 T cell autoreactivity to preproinsulin epitopes with very low human leucocyte antigen class I binding affinity. Clin. Exp. Immunol. 2012, 170:57-65.
2. Unger W.W., et al. Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T cells using combinatorial MHC multimers. J. Autoimmun. 2011, 37:151-159.
3. + T cells from patients with type 1 diabetes. Diabetes 2005, 54:92-99.
4. Tree T.I., et al. Naturally arising human CD4 T cells that recognize islet autoantigens and secrete interleukin-10 regulate proinflammatory T cell responses via linked suppression. Diabetes 2010, 59:1451-1460.
5. Eizirik D.L., et al. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr. Rev. 2008, 29:42-61.
6. O'Sullivan-Murphy B., Urano F. ER stress as a trigger for beta-cell dysfunction and autoimmunity in type 1 diabetes. Diabetes 2012, 61:780-781.
7. Schumacher T.N., Schreiber R.D. Neoantigens in cancer immunotherapy. Science 2015, 348:69-74.
8. Carmi Y., et al. The role of IL-1β in the early tumor cell-induced angiogenic response. J. Immunol. 2013, 190:3500-3509.
9. Maedler K., et al. Glucose-induced beta cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 2002, 110:851-860.
10. Piemonti L., et al. Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation. Diabetes 2002, 51:55-65.
11. Roep B.O., et al. Islet inflammation and CXCL10 in recent-onset type 1 diabetes. Clin. Exp. Immunol. 2010, 159:338-343.
12. Zhang J., et al. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. 2010, 21:41-48.
13. Eizirik D.L., et al. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat. Rev. Endocrinol. 2009, 5:219-226.
14. Quail D.F., Joyce J.A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 2013, 19:1423-1437.
15. Coppieters K.T., et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J. Exp. Med. 2012, 209:51-60.
16. Bull C., et al. Sweet escape: sialic acids in tumor immune evasion. Biochim. Biophys. Acta 2014, 1846:238-246.
17. Hicklin D.J., et al. HLA class I antigen downregulation in human cancers: T cell immunotherapy revives an old story. Mol. Med. Today 1999, 5:178-186.
18. De Boeck A., et al. Differential secretome analysis of cancer-associated fibroblasts and bone marrow-derived precursors to identify microenvironmental regulators of colon cancer progression. Proteomics 2013, 13:379-388.
19. Shiga K., et al. Cancer-associated fibroblasts: their characteristics and their roles in tumor growth. Cancers (Basel) 2015, 7:2443-2458.
20. Grivennikov S.I., et al. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
21. Motallebnezhad M., et al. The immunobiology of myeloid-derived suppressor cells in cancer. Tumor Biol. 2015, Published online November 25, 2015. 10.1007/s13277-015-4477-9.
22. Coppieters K.T., von Herrath M.G. Histopathology of type 1 diabetes: old paradigms and new insights. Rev. Diabet. Stud. 2009, 6:85-96.
23. Calderon B., et al. The pancreas anatomy conditions the origin and properties of resident macrophages. J. Exp. Med. 2015, 212:1497-1512.
24. Whitfield-Larry F., et al. Myeloid-derived suppressor cells are increased in frequency but not maximally suppressive in peripheral blood of type 1 diabetes mellitus patients. Clin. Immunol. 2014, 153:156-164.
25. Adeegbe D.O., Nishikawa H. Natural and induced T regulatory cells in cancer. Front. Immunol. 2013, 4:190.
26. Martin-Liberal J., et al. Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol. Immunother. 2015, 64:765-767.
27. + regulatory T cells prevent type 1 diabetes preceded by dendritic cell-dominant invasive insulitis by affecting chemotaxis and local invasiveness of dendritic cells. J. Immunol. 2010, 185:2493-2501.
28. + regulatory T cells. J. Immunol. 2008, 181:7350-7355.
29. Thompson J.A., et al. Autologous regulatory T cells for the treatment of type 1 diabetes. Curr. Diab. Rep. 2012, 12:623-632.
30. Beringer D.X., et al. T cell receptor reversed polarity recognition of a self-antigen major histocompatibility complex. Nat. Immunol. 2015, 16:1153-1161.
31. Ames B.N., Gold L.S. The causes and prevention of cancer: the role of environment. Biotherapy 1998, 11:205-220.
32. Shacter E., Weitzman S.A. Chronic inflammation and cancer. Oncology (Williston Park) 2002, 16:217-226. 229.
33. Greenman C., et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
34. Finnigan J.P., et al. Mutation-derived tumor antigens: novel targets in cancer immunotherapy. Oncology (Williston Park) 2015, 29:214812.
35. Cnop M., et al. The long lifespan and low turnover of human islet beta cells estimated by mathematical modelling of lipofuscin accumulation. Diabetologia 2010, 53:321-330.
36. Pan Q., et al. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 2008, 40:1413-1415.
37. Matlin A.J., et al. Understanding alternative splicing: towards a cellular code. Nat. Rev. Mol. Cell Biol. 2005, 6:386-398.
38. Grosso A.R., et al. Tissue-specific splicing factor gene expression signatures. Nucleic Acids Res. 2008, 36:4823-4832.
39. Venables J.P., et al. Cancer-associated regulation of alternative splicing. Nat. Struct. Mol. Biol. 2009, 16:670-676.
40. Stranzl T., et al. The cancer exome generated by alternative mRNA splicing dilutes predicted HLA class I epitope density. PLoS ONE 2012, 7:e38670.
41. van der Bruggen P., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
42. Chomez P., et al. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 2001, 61:5544-5551.
43. Andersen R.S., et al. High frequency of T cells specific for cryptic epitopes in melanoma patients. Oncoimmunology 2013, 2:e25374.
44. Eizirik D.L., et al. The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines. PLoS Genet. 2012, 8:e1002552.
45. Juan-Mateu J., et al. MECHANISMS IN ENDOCRINOLOGY: Alternative splicing: the new frontier in diabetes research. Eur. J. Endocrinol. 2016, 174:R225-R238.
46. Klein L., et al. Shaping of the autoreactive T cell repertoire by a splice variant of self protein expressed in thymic epithelial cells. Nat. Med. 2000, 6:56-61.
47. Diez J., et al. Differential splicing of the IA-2 mRNA in pancreas and lymphoid organs as a permissive genetic mechanism for autoimmunity against the IA-2 type 1 diabetes autoantigen. Diabetes 2001, 50:895-900.
48. de Jong V.M., et al. Alternative splicing and differential expression of the islet autoantigen IGRP between pancreas and thymus contributes to immunogenicity of pancreatic islets but not diabetogenicity in humans. Diabetologia 2013, 56:2651-2658.
49. Dogra R.S., et al. Alternative splicing of G6PC2, the gene coding for the islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP), results in differential expression in human thymus and spleen compared with pancreas. Diabetologia 2006, 49:953-957.
50. de Jong V.M., et al. Variation in the CTLA4 3'UTR has phenotypic consequences for autoreactive T cells and associates with genetic risk for type 1 diabetes. Genes Immun. 2016, 17:75-78.
51. Yewdell J.W., et al. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules?. J. Immunol. 1996, 157:1823-1826.
52. Eisenlohr L.C., et al. Rethinking peptide supply to MHC class I molecules. Nat. Rev. Immunol. 2007, 7:403-410.
53. Carbonnelle D., et al. The melanoma antigens MELOE-1 and MELOE-2 are translated from a bona fide polycistronic mRNA containing functional IRES sequences. PLoS ONE 2013, 8:e75233.
54. Lee H.J., et al. Expression of NY-ESO-1 in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and a good prognosis. Oncology 2015, 89:337-344.
55. Wang R.F., et al. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J. Exp. Med. 1996, 183:1131-1140.
56. Rapoport A.P., et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat. Med. 2015, 21:914-921.
57. Palam L.R., et al. Phosphorylation of eIF2 facilitates ribosomal bypass of an inhibitory upstream ORF to enhance CHOP translation. J. Biol. Chem. 2011, 286:10939-10949.
58. Marhfour I., et al. Expression of endoplasmic reticulum stress markers in the islets of patients with type 1 diabetes. Diabetologia 2012, 55:2417-2420.
59. Saulquin X., et al. +1 Frameshifting as a novel mechanism to generate a cryptic cytotoxic T lymphocyte epitope derived from human interleukin 10. J. Exp. Med. 2002, 195:353-358.
60. Shao M., et al. Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase. Cancer Res. 2009, 69:9192-9201.
61. Mehta K., Han A. Tissue transglutaminase (TG2)-induced inflammation in initiation, progression, and pathogenesis of pancreatic cancer. Cancers (Basel) 2011, 3:897-912.
62. Ahmed N., et al. Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 2005, 48:1590-1603.
63. Ryan B.J., et al. Oxidative post-translational modifications and their involvement in the pathogenesis of autoimmune diseases. Redox Biol. 2014, 2:715-724.
64. Spiro R.G. Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology 2002, 12:43R-56R.
65. van Lummel M., et al. Changing faces, unmasking the beta-cell: post-translational modification of antigens in type 1 diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 2013, 20:299-306.
66. Altrich-VanLith M.L., et al. Processing of a class I-restricted epitope from tyrosinase requires peptide N-glycanase and the cooperative action of endoplasmic reticulum aminopeptidase 1 and cytosolic proteases. J. Immunol. 2006, 177:5440-5450.
67. Skipper J.C., et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J. Exp. Med. 1996, 183:527-534.
68. Chen W., et al. CTL recognition of an altered peptide associated with asparagine bond rearrangement. Implications for immunity and vaccine design. J. Immunol. 1996, 157:1000-1005.
69. D'Angelo S., et al. UVA irradiation induces L-isoaspartyl formation in melanoma cell proteins. Free Radic. Biol. Med. 2001, 31:1-9.
70. Mohammed F., et al. Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self. Nat. Immunol. 2008, 9:1236-1243.
71. Cobbold M., et al. MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. Sci. Transl. Med. 2013, 5:203ra125.
72. Depontieu F.R., et al. Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:12073-12078.
73. van Lummel M., et al. Posttranslational modification of HLA-DQ binding islet autoantigens in type 1 diabetes. Diabetes 2014, 63:237-247.
74. Mannering S.I., et al. The insulin A-chain epitope recognized by human T cells is posttranslationally modified. J. Exp. Med. 2005, 202:1191-1197.
75. McLaughlin R.J., et al. Human islets and dendritic cells generate post-translationally modified islet auto-antigens. Clin. Exp. Immunol. 2016, Published online February 9, 2016. 10.1111/cei.12775.
76. McGinty J.W., et al. Recognition of posttranslationally modified GAD65 epitopes in subjects with type 1 diabetes. Diabetes 2014, 63:3033-3040.
77. Barrett J.C., et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat. Genet. 2009, 41:703-707.
78. Wenzlau J.M., et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:17040-17045.
79. Achenbach P., et al. Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia 2009, 52:1881-1888.
80. Oikawa Y., et al. Insulinoma may mask the existence of type 1 diabetes. Diabet. Med. 2012, 29:e138-e141.
81. Maddison P., et al. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 1999, 353:117-118.
82. Wirtz P.W., et al. HLA class I and II in Lambert-Eaton myasthenic syndrome without associated tumor. Hum. Immunol. 2001, 62:809-813.
83. Rizvi N.A., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015, 348:124-128.
84. Gubin M.M., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014, 515:577-581.
85. Melief C.J. Mutation-specific T cells for immunotherapy of gliomas. N. Engl. J. Med. 2015, 372:1956-1958.
86. Hughes J., et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 2015, 38:e55-e57.
87. Unger W.W., et al. Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur. J. Immunol. 2009, 39:3147-3159.
88. Rodriguez-Calvo T., et al. Increased immune cell infiltration of the exocrine pancreas: a possible contribution to the pathogenesis of type 1 diabetes. Diabetes 2014, 63:3880-3890.
89. Krogvold L., et al. Insulitis and characterisation of infiltrating T cells in surgical pancreatic tail resections from patients at onset of type 1 diabetes. Diabetologia 2016, 59:492-501.
90. Gorasia D.G., et al. Pancreatic beta cells are highly susceptible to oxidative and ER stresses during the development of diabetes. J. Proteome Res. 2015, 14:688-699.
91. Marroqui L., et al. Pancreatic α cells are resistant to metabolic stress-induced apoptosis in type 2 diabetes. EBioMedicine 2015, 2:378-385.
92. Scheuner D., Kaufman R.J. The unfolded protein response: a pathway that links insulin demand with beta-cell failure and diabetes. Endocr. Rev. 2008, 29:317-333.
93. Unger R.H., Orci L. The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1975, 1:14-16.
94. Drucker D.J. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 2013, 62:3316-3323.
95. Ellingsgaard H., et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat. Med. 2011, 17:1481-1489.
96. Vigneron N., et al. An antigenic peptide produced by peptide splicing in the proteasome. Science 2004, 304:587-590.
97. Michaux A., et al. A spliced antigenic peptide comprising a single spliced amino acid is produced in the proteasome by reverse splicing of a longer peptide fragment followed by trimming. J. Immunol. 2014, 192:1962-1971.
98. Dalet A., et al. Splicing of distant peptide fragments occurs in the proteasome by transpeptidation and produces the spliced antigenic peptide derived from fibroblast growth factor-5. J. Immunol. 2010, 184:3016-3024.
99. Delong T., et al. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science 2016, 351:711-714.